Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Monoclonal Antibody Reduces Frequency of Asthma Exacerbations
March 31st, 2000
Findings from two Phase III studies show that treatment with anti-IgE, a recombinant humanized monoclonal antibody to immunoglobulin E, resulted in a decrease in the frequency of asthma exacerbations and in the use of steroids and rescue medication in both children (6-12 years) and adults (12-75 years), compared to placebo. The results were presented at the 56th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI), held in San Diego, California. Of the 525 patients in the adult study and 334 patients in the pediatric study, 55% of children and 40% of adults receiving anti-IgE treatment completely withdrew from inhaled...
Source: Drug Week (2000-03-31)
|
